Graham Capital Management’s Medifast MED Stock Holding History

Graham Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,290	Closed	-$241K	–	1233
2024 Q1	$241K	Buy	+6,290	New	+$305K	﹤0.01%	851

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Graham Capital Management's MED Position: Q2 2024 in Review

Graham Capital Management sold out of Medifast (MED) in Q2 2024, closing a stake of 6,290 shares — an estimated $241K sold.

Graham Capital Management first reported a position in MED in Q1 2024 and held it in 1 quarter. The position peaked at $241K in Q1 2024. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

Graham Capital Management reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
Graham Capital Management sold 6,290 Medifast shares in Q2 2024, an estimated $241K.
Graham Capital Management first reported a position in Medifast in Q1 2024 and held it in 1 quarter.
Graham Capital Management's Medifast position peaked at $241K in Q1 2024.
158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.